Rosuvastatin Calcium
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CYP2C19 Poor
Conditions
CYP2C19 Poor, Extensive Metabolizers
Trial Timeline
Sep 1, 2008 → Feb 1, 2009
NCT ID
NCT00766025About Rosuvastatin Calcium
Rosuvastatin Calcium is a phase 1 stage product being developed by AstraZeneca for CYP2C19 Poor. The current trial status is completed. This product is registered under clinical trial identifier NCT00766025. Target conditions include CYP2C19 Poor, Extensive Metabolizers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00766025 | Phase 1 | Completed |
| NCT00240318 | Phase 3 | Completed |
| NCT00225589 | Phase 3 | Completed |